Cargando…
Preclinical Efficacy and Toxicology Evaluation of RAC1 Inhibitor 1A-116 in Human Glioblastoma Models
SIMPLE SUMMARY: Malignant gliomas are the most common primary central nervous system tumors in adults. Currently, this disease is associated with poor prognosis and is virtually incurable. There is a need to find novel targets and treatments to improve patient survival. This study shows the preclini...
Autores principales: | Cardama, Georgina A., Maggio, Julian, Valdez Capuccino, Lucas, Gonzalez, Nazareno, Matiller, Valentina, Ortega, Hugo H., Perez, German R., Demarco, Ignacio A., Spitzer, Eduardo, Gomez, Daniel E., Lorenzano Menna, Pablo, Alonso, Daniel F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562863/ https://www.ncbi.nlm.nih.gov/pubmed/36230732 http://dx.doi.org/10.3390/cancers14194810 |
Ejemplares similares
-
Computational and in vitro Pharmacodynamics Characterization of 1A-116 Rac1 Inhibitor: Relevance of Trp56 in Its Biological Activity
por: González, Nazareno, et al.
Publicado: (2020) -
Preclinical Development of Novel Rac1-GEF Signaling Inhibitors using a Rational Design Approach in Highly Aggressive Breast Cancer Cell Lines
por: Cardama, Georgina A, et al.
Publicado: (2014) -
Proapoptotic and antiinvasive activity of Rac1 small molecule inhibitors on malignant glioma cells
por: Cardama, Georgina A, et al.
Publicado: (2014) -
Pharmacological Rac1 inhibitors with selective apoptotic activity in human acute leukemic cell lines
por: Cabrera, Maia, et al.
Publicado: (2017) -
Timing of Novel Drug 1A-116 to Circadian Rhythms Improves Therapeutic Effects against Glioblastoma
por: Trebucq, Laura Lucía, et al.
Publicado: (2021)